ReviewTouchREVIEWS in endocrinology2022

Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes.

Shizuka KanekoPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.